LENZ Therapeutics
LENZ· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -44.6% in FY2025
Evert Schimmelpennink is the CEO of LENZ Therapeutics and was paid $7.0M in FY2025 (Dec), up 1%.
Pay$100 in the stock at the end of FY22 → $102
Executives3
See all- 1Evert SchimmelpenninkPresident and Chief Executive OfficerFY2025
- 2Marc OdrichChief Medical OfficerFY2025
- 3Shawn OlssonChief Commercial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allLENZ Therapeutics paid its 3 named executives $11.9M in total in FY2025 (Dec). CEO Evert Schimmelpennink was paid $7.0M of that.
| Name | |||
|---|---|---|---|
| Evert SchimmelpenninkPresident and Chief Executive Officer | |||
| Marc OdrichChief Medical Officer | |||
| Shawn OlssonChief Commercial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for LENZ Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- Jeff GeorgeChair · 1 yr on the boardIndependentNominating and Corporate Governance (Chair)—Paid as an executive
- Kimberlee C. DrapkinDirector · 2 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
- Evert SchimmelpenninkDirector · 1 yr on the boardNot independent—Paid as an executive
- Frederic GuerardDirector · 1 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
- Zachary ScheinerDirector · 1 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Shared directors
- iBioEvert Schimmelpennink1 shared
- NkartaZachary Scheiner1 shared
Activity
Filings5
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 24, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 19, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2024 | FY2023 |
